Narrator: This is Science Today. Lung cancer kills more Americans every year than breast, prostate, colon and pancreas cancers combined. Yet, there is still no standard approach to lung cancer screening. That's why the National Institute of Health is funding a huge national lung screening trial. Jonathan Goldin, is co-investigator of the site study at the UCLA Jonsson Cancer Center.
Goldin: The national lung screening trial, NLST, is a multi-center study who's primary objective is to study whether screening for lung cancer in at risk individuals with either chest x-ray or CT is an effective mode of screening.
Narrator: Eligible study participants will undergo three years of screening, using the modality they were randomly assigned.
Goldin: They will also complete questionnaires that follow very carefully what's happened to them, not only medically, but in terms of the impact in a subgroup of patients, the impact of screening on the psychology of the patient, the health economy of the patient, as well as on the society in which screening is being done will be looked at.
Narrator: For Science Today, I'm Larissa Branin.